P2Y

Glioblastoma (GBM) is the most aggressive and lethal among the primary brain tumors, with a low survival rate and resistance to radio and chemotherapy. The P2Y(12) is an adenosine diphosphate (ADP) purinergic chemoreceptor, found mainly in platelets. In cancer cells, its activation has been described to induce proliferation and metastasis. Bearing in mind the need to find new treatments for GBM, this study aimed to investigate the role of the P2Y(12)R in the proliferation and migration of GBM cells, as well as to evaluate the expression of this receptor in patients’ data obtained from the TCGA data bank. Here, we used the P2Y(12)R antagonist, ticagrelor, which belongs to the antiplatelet agent’s class. The different GBM cells (cell line and patient-derived cells) were treated with ticagrelor, with the agonist, ADP, or both, and the effects on cell proliferation, colony formation, ADP hydrolysis, cell cycle and death, migration, and cell adhesion were analyzed. The results showed that ticagrelor decreased the viability and the proliferation of GBM cells. P2Y(12)R antagonism also reduced colony formation and migration potentials, with alterations on the expression of metalloproteinases, and induced autophagy in GBM cells. Changes were observed at the cell cycle level, and only the U251 cell line showed a significant reduction in the ADP hydrolysis profile. TCGA data analysis showed a higher expression of P2Y(12)R in gliomas samples when compared to the other tumors. These data demonstrate the importance of the P2Y(12) receptor in gliomas development and reinforce its potential as a pharmacological target for glioma treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11302-022-09888-w.